Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
21 nov. 2023 16h00 HE
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
16 nov. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsi
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
07 nov. 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
02 nov. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
02 oct. 2023 13h17 HE
|
Praxis Precision Medicines, Inc.
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
27 sept. 2023 16h15 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
31 août 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
28 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
09 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA PRAX-628 Phase 1 study showed consistent safety profile and target engagement in...